← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS › INTESTINAL ANTIINFECTIVES › Antibiotics
fidaxomicin
A07AA12
Forms & Strengths
- Oral tablet: 200 mg
- Oral suspension: 40 mg/mL
Adult Dosing
- Clostridioides difficile infection: 200 mg orally twice daily for 10 days
Pediatric Dosing
- Pediatric patients (6 months and older): 200 mg orally twice daily for 10 days (weight-based dosing using oral suspension for children < 12.5 kg)
Indications
- Treatment of Clostridioides difficile infections (CDI) in adults and pediatric patients aged 6 months and older
- Reduction of recurrence of Clostridioides difficile infection
Mechanism of Action
- Macrolide antibacterial that inhibits bacterial RNA synthesis by binding to RNA polymerase, causing inhibition of protein synthesis and bacterial cell death with a narrow spectrum targeting C. difficile
Contraindications
- Hypersensitivity to fidaxomicin or any of its excipients
Adverse Reactions
- Nausea
- Vomiting
- Abdominal pain
- Gastrointestinal hemorrhage
- Anemia
- Neutropenia
- Hypersensitivity reactions (rash, pruritus, angioedema)
Drug Interactions
- P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine, ketoconazole, erythromycin) may increase systemic exposure of fidaxomicin, though clinical significance is generally low due to minimal systemic absorption
Curated Content: Needs Vetting Before Put to Clinical Use